1. Clinical outcomes of chronic kidney disease patients treated with everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES)
- Author
-
Minako Yamaoka-Tojo, Takehiro Hashikata, Sayaka Namba, Ichiro Takeuchi, Taiki Tojo, Lisa Kitasato, Junya Ako, Ryo Kameda, Yuki Ikeda, Takao Shimohama, and Nobuhiro Sato
- Subjects
Male ,medicine.medical_specialty ,Paclitaxel ,medicine.medical_treatment ,Everolimus eluting stent ,Urology ,Administration, Oral ,Kaplan-Meier Estimate ,Coronary Angiography ,chemistry.chemical_compound ,Percutaneous Coronary Intervention ,Renal Dialysis ,Internal medicine ,medicine ,Humans ,In patient ,Everolimus ,cardiovascular diseases ,Renal Insufficiency, Chronic ,Target lesion revascularization ,Aged ,Proportional Hazards Models ,Pharmacology ,business.industry ,Incidence (epidemiology) ,Drug-Eluting Stents ,General Medicine ,equipment and supplies ,medicine.disease ,body regions ,Treatment Outcome ,chemistry ,Cardiovascular Diseases ,Multivariate Analysis ,Cardiology ,Female ,Hemodialysis ,business ,human activities ,Mace ,Follow-Up Studies ,Kidney disease - Abstract
The target lesion revascularization of paclitaxel-eluting stents (PES) has been reported to be lower than that of sirolimus-eluting stents in patients on hemodialysis (HD). However, the comparison of PES and second generation drug-eluting stents in CKD patients has not been fully investigated. We compared clinical outcomes of everolimus-eluting stents (EES) and PES in CKD patients.Hundred and forty seven CKD patients (eGFR60mLmin(-1)1.73m(-2)) treated with PES (n=74, from May 2007 to December 2009) and EES (n=73, from January 2010 to January 2013) were enrolled in the study. Major adverse cardiac events (MACEs) were defined as death, non-fatal myocardial infarction, and ischemia driven target lesion revascularization.The incidence of 36-month MACE was significantly lower in EES, non-HD group compared to PES, non HD group (0% in EES group and 13.5% in PES group, respectively, P0.01). There was no significant difference in MACE between EES and PES in HD patients (5.4% in PES group and 5.5% in EES group, P=0.98). In multivariate analysis, PES group and PES ISR were independent factors for worse incidence of MACE.In CKD patients, PES was associated with worse clinical outcomes in non-HD patients as compared with EES.
- Published
- 2015
- Full Text
- View/download PDF